MedTech Acquisition Corporation is a blank check company organized for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses primarily operating in the healthcare sector in the United States.
Company profile
Ticker
TLSI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MedTech Acquisition Corp, MedTech Acquisition Corporation
SEC CIK
Corporate docs
IRS number
853009869
TLSI stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
25 Apr 24
EFFECT
Notice of effectiveness
25 Apr 24
POS AM
Prospectus update (post-effective amendment)
16 Apr 24
POS AM
Prospectus update (post-effective amendment)
16 Apr 24
8-K
Changes in Registrant's Certifying Accountant
15 Apr 24
S-8
Registration of securities for employees
11 Apr 24
10-K
2023 FY
Annual report
11 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
1 Apr 24
8-K
Results of Operations and Financial Condition
11 Mar 24
Transcripts
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.63 mm | 21.63 mm | 21.63 mm | 21.63 mm | 21.63 mm | 21.63 mm |
Cash burn (monthly) | (no burn) | (no burn) | 6.16 mm | 4.65 mm | 7.15 mm | 4.13 mm |
Cash used (since last report) | n/a | n/a | 42.52 mm | 32.11 mm | 49.38 mm | 28.48 mm |
Cash remaining | n/a | n/a | -20.89 mm | -10.48 mm | -27.74 mm | -6.85 mm |
Runway (months of cash) | n/a | n/a | -3.4 | -2.3 | -3.9 | -1.7 |
Institutional ownership, Q3 2023
56.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 28 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 942.75 mm |
Total shares | 15.02 mm |
Total puts | 0.00 |
Total calls | 332.25 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Equity AB Frankenius | 6.40 mm | $0.00 |
Unique Diamond Investments | 1.55 mm | $0.00 |
Christopher C Dewey | 1.52 mm | $0.00 |
Mats Wahlstrom | 1.37 mm | $0.00 |
Lombard International Assurance | 1.36 mm | $0.00 |
Magnetar Financial | 879.51 k | $330.87 mm |
Deerfield Management | 333.33 k | $126.67 mm |
Polar Asset Management Partners | 285.86 k | $108.63 mm |
Exos TFP | 167.61 k | $63.69 mm |
Kim | 167.57 k | $63.04 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Feb 24 | Szela Mary T | Common Stock | Grant | Acquire A | No | No | 0 | 84,899 | 0.00 | 364,862 |
13 Feb 24 | Szela Mary T | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 9.4 | 288,750 | 2.71 mm | 288,750 |
12 Feb 24 | Bryan F. Cox | Common Stock | Grant | Acquire A | No | No | 0 | 14,752 | 0.00 | 86,696 |
12 Feb 24 | Bryan F. Cox | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 9.5 | 63,750 | 605.63 k | 63,750 |
12 Feb 24 | Richard Marshak | Common Stock | Grant | Acquire A | No | No | 0 | 14,752 | 0.00 | 27,251 |
12 Feb 24 | Richard Marshak | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 9.5 | 63,750 | 605.63 k | 63,750 |
12 Feb 24 | Jennifer Stevens | Common Stock | Grant | Acquire A | No | No | 0 | 14,752 | 0.00 | 32,783 |
12 Feb 24 | Jennifer Stevens | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 9.5 | 63,750 | 605.63 k | 63,750 |
12 Feb 24 | Jodi Devlin | Common Stock | Grant | Acquire A | No | No | 0 | 17,500 | 0.00 | 17,500 |
12 Feb 24 | Jodi Devlin | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 9.5 | 105,000 | 997.50 k | 105,000 |
News
TriSalus Life Sciences Q4 2023 GAAP EPS $(1.56) Misses $(0.69) Estimate, Sales $5.721M Beat $5.453M Estimate
1 Apr 24
Earnings Scheduled For April 1, 2024
1 Apr 24
TriSalus Life Sciences Expects Sales To Grow In Excess Of 50% In 2024; Says Currently In The Process Of Obtaining Additional Liquidity To Fund Operations Through 2024
11 Mar 24
TriSalus Life Sciences Reports Preliminary Q4 Sales Of Approximately $5.7M, Representing 77% Growth Versus 2022; Est $5.453M
11 Mar 24
Press releases
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
26 Mar 24
TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
11 Mar 24
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for "Nelitolimod" as the Nonproprietary Drug Name for SD-101
7 Mar 24
ORI Capital Raises $260 Million for Second Life Sciences Fund
22 Feb 24